The global neuro immunoassay market is projected to experience significant growth, with a valuation of US$ 2,616.1 million in 2023 and expected to reach US$ 5,303.1 million by 2033. The market is set to expand at a CAGR of 7.3% over the forecast period.
Neuro immunoassays, which are key diagnostic tools used to detect biomarkers associated with neurological diseases, are becoming increasingly vital for early diagnosis and disease management. The market’s growth is driven by the rising prevalence of neurological disorders, such as Alzheimer’s, Parkinson’s, and multiple sclerosis, along with advancements in immunoassay technologies that improve diagnostic accuracy.
The demand for neuro immunoassays is also supported by the growing focus on personalized medicine, where accurate biomarkers play a critical role in tailoring treatment plans. Additionally, increasing investments in neurological research and diagnostic innovation are expected to drive the continued development and adoption of these assays.
Get the Comprehensive Full Report Now – https://www.futuremarketinsights.com/reports/neuro-immunoassay-market
Key Takeaways:
- The neuro immunoassay market is projected to grow from US$ 2,616.1 million in 2023 to US$ 5,303.1 million by 2033, at a CAGR of 7.3%.
- The rising prevalence of neurological disorders and advancements in diagnostic technologies are key drivers of market growth.
- Increased focus on personalized medicine and biomarker-based diagnostics further supports market expansion.
- Growing investments in neurological research and diagnostics are expected to fuel the development of innovative neuro immunoassays.
Market Drivers
- Increasing Incidence of Neurological Disorders: The rising prevalence of neurological conditions is driving demand for effective diagnostic tools, including neuro immunoassays that help in identifying specific biomarkers.
- Advancements in Immunoassay Technology: Continuous innovations in immunoassay techniques are enhancing their accuracy and reliability, making them essential for clinical diagnostics and research.
- Growing Focus on Personalized Medicine: The shift towards personalized treatment approaches in neurology is propelling the adoption of neuro immunoassays, which can tailor therapies based on individual biomarker profiles.
- Rising Research Activities: Increased funding and research initiatives focused on neurological diseases are promoting the development and application of neuro immunoassays in both clinical and laboratory settings.
Regional Insights
- North America is expected to dominate the market, accounting for a significant share due to advanced healthcare infrastructure and a strong emphasis on research and development.
- The European region is also anticipated to hold a substantial market share, driven by high disposable incomes and increasing demand for innovative diagnostic solutions.
Challenges
- High Costs of Advanced Testing: The costs associated with advanced neuro immunoassay tests may limit accessibility for some healthcare providers and patients.
- Regulatory Hurdles: Navigating complex regulatory requirements for diagnostic tests can pose challenges for manufacturers and developers in the market.
Who are the Key Players in the Neuro Immunoassay Market?
Some of the key players in the neuro immunoassay market are: Intrinsic LifeSciences, Danaher Corporation (Beckman Coulter), Becton Dickinson and Company, Akers Biosciences, Inc., Abbott Laboratories, Inc, EDP Biotech Corporation, Hologic (Gen-Probe), Biomérieux, and others.
Recent Development in the Neuro Immunoassay Market:
- In May 2023, Beckman Coulter introduced a new immunoassay analyzer known as DxI 9000 Access. This innovative analyzer has the capability to perform up to 215 tests per hour per square meter (tests/h/m²).
- In March 2023, the release of the Lumipulse G NfL CSF and Lumipulse G NfL Blood tests was officially announced by H.U. Group Holdings Inc. and Fujirebio. The completely automated random-access LUMIPULSE® G immunoassay systems are intended to work with these assays. They utilize CLEIA (chemiluminescent enzyme immunoassay) technology. Neurofilament light (NfL) can potentially be quantitatively measured using the tests in human plasma/serum and cerebral spinal fluid (CSF), respectively.
- In January 2023, the United States FDA granted approval for Leqembi (lecanemab-irmb). The approval was obtained through the Accelerated Approval pathway.. It belongs to a new category of medications that target the fundamental pathophysiology of the Alzheimer’s disease. This approval marks a significant advancement in the ongoing efforts to effectively treat Alzheimer’s disease.
- In September 2022, QIAGEN partnered with Neuron23. Their collaboration aims to develop an assay for detecting biomarkers discovered by Neuron23. This assay is intended to predict the responsiveness of Parkinson’s disease to the LRRK2 inhibitor.
- In July 2022, Labcorp launched a new test. This test offers concrete proof of neuronal damage and neurodegeneration. The Neurofilament Light Chain (NFL) blood test is the first of its kind. It enables medical professionals to spot and confirm neurodegenerative disease symptoms. With this test, physicians can offer a more effective and efficient path to diagnosis and treatment for patients.
- In June 2022, Becton Dickinson and Company which is global leader in medical technology, and a leading private equity firm Frazier Healthcare Partners who focus on healthcare sector – announced an agreement for the former to acquire Parata Systems which is an innovative provider of pharmacy automation solutions for $1.525 billion.
Key Segments of the Neuro Immunoassay Market
By Technology:
- Radioimmunoassays (RIA)
- Polymerase Chain Reaction (PCR)
- ELISA
- Western Blot
- Rapid Tests
- ELISPOT
By Product Type:
- Reagents and Kits
- Analysers
By Application:
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy (SMA)
By End User:
- Hospitals
- Clinics
- Academic Organizations
- Biopharmaceutical Companies
- Pharmaceutical Companies
- Others
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
- Europe
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
